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The process of aging affects the brain in multiple ways and 
causes a progressive decline in neuronal and cognitive   function. 
One of the major underlying processes in brain aging is the 
  deterioration of the cerebrovascular system, as it is often seen 
in age-related disorders and dementia (Buee et al., 1994; De 
Jong et al., 1997; Farkas et al., 2000; Farkas and Luiten, 2001; 
Riddle et al., 2003; Iadecola, 2004). Aging is associated with 
changes in microvascular plasticity and a reduced microvascular 
 density  (Amenta et al., 1995; Sonntag et al., 1997, 2000; Lynch 
et al., 1999). In addition, aging causes a progressive increase 
in   microvascular abnormalities that affect blood-brain   barrier 
function, including surface irregularities (Lee et  al., 2000), 
  thickening of the basement membrane and ﬁ  brous collagen 
deposits in the capillary wall (Burns et al., 1981; Keuker et al., 
2000). Such abnormalities may decrease perfusion of the brain, 
leading to a decrease in nutrient and oxygen supply, which may 
be an important component in the development of age-related 
cognitive impairment (De Jong et al., 1997; Farkas et al., 2000, 
2007; Farkas and Luiten, 2001; Riddle et al., 2003) and render 
the brain vulnerable to degenerative mechanisms. Therefore, 
the cerebrovascular system is an important target in preserving 
neuronal and cognitive health.
Since resveratrol has a potentially beneﬁ  cial inﬂ  uence on sev-
eral parameters involved in aging, including vascular function 
(Labinskyy et  al., 2006) we here examine the neurobiological 
effects of long term, regular resveratrol intake in aged mice. We 
hypothesized that resveratrol preserves neuronal health and cogni-
tive function in aging mice by delaying age-dependent cerebrov-
ascular deterioration. In order to determine the effects of aging 
and long-term resveratrol administration on behavioral level, we 
INTRODUCTION
Resveratrol (trans-3,5,4′-trihydroxystilbene) is a natural  polyphenol, 
enriched in grapes and red wine, with potential beneﬁ  cial effects 
on human health. In fact, the lower incidence of cardiovascular 
disease in wine drinking countries despite a diet high in saturated 
fat, a phenomenon referred to as the ‘French paradox’, has been 
associated with the actions of resveratrol (Renaud and de Lorgeril, 
1992; Kopp, 1998; Wu et al., 2001).
Resveratrol exerts a myriad of physiological effects (for reviews 
see Fremont, 2000; Baur and Sinclair, 2006) including antioxidant 
(Frankel et al., 1993; Fremont et al., 1999; Mizutani et al., 2001; Jang 
and Surh, 2003), phytoestrogenic (Gehm et al., 1997),  vasorelaxing 
(Fitzpatrick et al., 1993; Jager and Nguyen-Duong, 1999; Das et al., 
2005), anti-inﬂ  ammatory and anti-carcinogenic activity (Jang et al., 
1997). In addition, resveratrol has been reported to extend life span 
in yeast (Howitz et al., 2003) and promote survival in mice on a 
high-caloric diet (Baur et al., 2006).
Besides effects on general health and life span, a number of in vivo 
studies suggest that injection of resveratrol during the induction of 
cerebral ischemia protects the brain against acute neurodegenera-
tion (Wang et al., 2002; Lu et al., 2006). Also, dietary resveratrol sup-
plementation was able to reduce ischemia-induced neuronal damage 
(Virgili and Contestabile, 2000; Dong et al., 2008). In hippocampal 
slices, cell death and altered neuronal responses due to oxygen and 
glucose deprivation were attenuated by resveratrol (Zhang et al., 
2008). Considering its health and survival promoting effects and its 
neuroprotective potential after acute treatment in models of neuro-
degeneration, it is an   intriguing   question whether chronic dietary 
resveratrol could protect against slow age-related decline in brain 
function and cognitive   performance in normal mice.
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measured general exploratory activity in an open-ﬁ  eld test and 
analyzed   learning and memory performance in a   hippocampus-
dependent spatial Y-maze task. To assess cerebrovascular condition, 
we performed detailed structural analysis of cerebral microvessels 
in the cortex and hippocampus by means of electron microscopy. 
In addition, we characterized potential alterations in the cholinergic 
neurotransmitter system, a system often affected in age-related cog-
nitive decline, by determining histochemically labeled cell numbers 
and ﬁ  ber density.
MATERIALS AND METHODS
ANIMALS AND HOUSING
The experiment was performed with male C57Bl/6 mice (Harlan, 
Horst, The Netherlands). The procedures concerning animal care 
and treatment were approved by the ethical committee for the use of 
experimental animals of the University of Groningen. Animals were 
individually housed under a 12-h light/12-h dark cycle with lights 
on at 8:00 AM. Food and drinking water were provided ad libitum, 
except for the period of behavioral testing as described below. The 
experiment started with 60 mice, half of which served as control 
(CON) and half of which received resveratrol in their food from the 
age of 1 year onwards (RES). Between the ages of 18 and 20 months, 
spatial learning performance of the animals was studied in a Y-maze 
test. At the age of 24 months, brains were collected and processed 
for histochemical analysis of cholinergic parameters and electron 
microscopic analysis of microvascular ultrastructure in the cortex 
and hippocampus.
RESVERATROL SUPPLEMENTATION
Resveratrol was provided in the food (150 µg resveratrol/gram food; 
Hope Farms, Woerden, The Netherlands). To rule out differences 
in food intake between animals on a control diet and resveratrol-
supplemented diet, food intake and body weight were monitored 
every 2 weeks. To establish whether resveratrol provided in the food 
enters the circulation, we performed a pilot experiment in which 
we collected blood from six mice by decapitation after 1 day and 
30 days of supplementation. Plasma concentrations of resveratrol 
were measured (Danone Research, Wageningen, The Netherlands). 
After 1 day of supplementation, resveratrol levels in the plasma were 
88.5 ± 20.5 µg/l in the last hour of the dark or active phase, when 
mice consume most of their food, and 41.0 ± 2.6 µg/l in the last hour 
of the light phase or resting phase (n = 3 each). After 1 month of 
supplementation, levels were 102.7 ± 35.3 µg/l and 30.7 ± 11.2 µg/l 
at the end of active phase and rest phase, respectively (n = 3 each). 
These measurements conﬁ  rmed that resveratrol ingested via the 
food indeed entered the circulation and that levels appeared to ﬂ  uc-
tuate over the day in a fashion that paralleled food intake.
OPEN-FIELD TEST
To examine general exploratory activity, mice were subjected to 
an open-ﬁ  eld test for 5 min. The open ﬁ  eld consisted of a circular 
arena with a diameter of 120 cm surrounded by a 60-cm high wall. 
The arena was divided in two imaginary concentric zones, a cen-
tral zone (60-cm diameter) and an outer zone (120-cm  diameter). 
Position and locomotion of the mice were recorded and analyzed 
with a computerized video tracking system (Ethovision, Noldus 
Information Technology, Wageningen, The Netherlands). The 
number of visits, total time and distance spent in each of the two 
zones was measured and used to analyze exploration patterns and 
general activity. The open-ﬁ  eld arena was thoroughly cleaned 
before a new animal was tested.
Y-MAZE LEARNING
To examine cognitive performance, the mice were subjected to a 
Y-maze test in which they had to learn the location of a food reward 
in one of two accessible choice arms (Havekes et al., 2007). The test 
was conducted in a tubular, transparent plexiglass Y-maze consist-
ing of a start arm and two test arms forming the Y. All arms of the 
maze were 27.5 cm long, had a diameter of 5 cm, and were at a 120° 
angle from each other. The home cages of the mice were equipped 
with a small sliding door that connected to the starting arm. One 
of the two test arms was baited with a food reward consisting of 
small crumbs of the regular food. Food crumbs were also placed 
below perforations at the end of the other test arm to prevent ani-
mals from discriminating between baited and non-baited arms by 
olfactory cues. Small grey plastic blocks (1 cm high) were placed 
4 cm from the end of the arms to prevent visual inspection for food 
presence from a distance. A guillotine door halfway each arm could 
be operated manually from the experimenter’s position and was 
used to allow animals only one choice in each training trial. The 
experimental room contained visual cues, which served as distal 
spatial cues. To assure sufﬁ  cient motivation for the test, the animals 
were food restricted to about 85% of their original body weight. 
Food restriction started 3 days before the test. The animals received 
their food daily between 16:00 and 18:00 PM.
The Y-maze test took place during the ﬁ  rst half of the light 
phase between 10:00 and 14:00 in a room adjacent to the home 
cage room. The animals were carried in their home cage to the 
experimental room and the cage was then connected to the Y-maze. 
On the ﬁ  rst day of the test animals were habituated to the maze by 
allowing them to freely explore the arms for 5 min. They further 
received two habituation trials during which they had access to 
the right arm only on the ﬁ  rst trial and the left arm only on the 
second trial, with arms baited during each habituation trial. After 
the habituation day, mice received a daily training session consist-
ing of eight trials consecutively. During the entire training phase, 
either the right or left arm was baited. This was constant for a 
given animal, but randomized between animals and treatments. 
When during a trial an animal visited one of the two accessible 
arms, the non-visited arm was closed. After the animal retreated to 
the start box, the start arm connected to the start box was blocked 
preventing re-entrance of the maze. After cleaning all arms with 
damped paper cloth, and re-baiting the same arm, the animal was 
again allowed to explore either the right or left test arm. A visit to 
the baited arm was recorded as a correct trial. Mice were trained 
in the Y-maze for 3 consecutive days and 10 days after the ﬁ  nal 
training day, animals were subjected to another series of eight 
trials to test their memory.
TISSUE PROCESSING
At the age of 24 months animals were sacriﬁ  ced for histochemi-
cal and electron microscopical analysis. Mice were anaesthetized 
by a high dose of sodium pentobarbital (Nembutal, 60 mg/kg 
bodyweight) and transcardially perfused with heparinized saline Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 3
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followed by 4% phosphate buffered paraformaldehyde. After 
  perfusion, brains were carefully removed from the skull and kept 
in 0.01 M PBS overnight. A random subset of 18 brains (n = 9 for 
both CON and RES) were further processed for electron micros-
copy. Another random subset of 22 brains (n = 11 for both CON 
and RES) was used for histological analysis.
HISTOLOGY
For histology, brain tissue was cryoprotected in 30% sucrose in 
0.1 M phosphate buffer (PB) for 48 h after which 20 µm sections 
were cut with a cryostat (Leica CM3050). To analyze possible 
changes in cholinergic cells and ﬁ  bers, an enzymatic staining for 
acetylcholinesterase (AChE) was performed in every 10th section. 
Sections were postﬁ  xed in a 2.5% glutardialdehyde solution in PB 
overnight at 4°C. AChE histochemistry was carried out according 
to previously described methods (Hedreen et al., 1985). In brief, 
sections were incubated in an acetylthiocholine-iodide containing 
incubation buffer, followed by sodiumsulﬁ  de and ﬁ  nally intensi-
ﬁ  ed with a 0.1% silver nitrate solution. Cell bodies positive for 
AChE were manually counted by an experimenter blind for the 
treatment group in two representative sections per animal, con-
taining the nucleus basalis (around bregma −0.7). Cell numbers 
were expressed as average number per section. AChE ﬁ  ber den-
sity measurements were performed in two sections per animal 
by a computerized image analysis system (Quantimet, Leica). A 
contour was drawn around the stratum radiatum and stratum 
oriens of the CA1 region of the dorsal hippocampus in which ﬁ  ber 
density was computed as a percentage of the total surface area 
covered by cholinergic ﬁ  bers. The same procedure was used in the 
molecular layer of the dentate gyrus of the dorsal hippocampus 
and for two contours per section in the parietal cortex II between 
bregma −1.4 and −2.3.
ELECTRON MICROSCOPY
After perfusion, 18 brains were prepared for electron microscopy 
(de Wilde et al., 2002; Farkas et al., 2003). Brieﬂ  y, tissue blocks 
of the frontoparietal cortex and the dorsal hippocampus were 
incubated in an aqueous solution of 1% OsO4 and 5% K2Cr4O7 
(1:1) after thorough rinsing. Subsequently, the samples were 
dehydrated, incubated in 1% uranyl-acetate, and embedded in 
glycide ether. Semi-thin sections (0.3 µm) were cut on an ultra-
microtome and stained on object glasses with a 1:1 mixture of 
1% ethylene blue and 1% Azure II blue. The samples were then 
coverslipped with DPX and analyzed under a light microscope. 
Then, 90-nm ultra thin sections were cut of the same blocks and 
three non-serial sections were collected on 200 mesh copper grids. 
Subsequently, preparations were contrasted with 5% uranyl-
acetate and Reynolds lead-citrate solution. Finally, the samples 
were analyzed and photographs were taken with a Philips TM10 
transmission electron microscope.
For quantitative analysis, approximately 4000  µm2 tissue 
  surface was scanned systematically in each region, and 61 ± 10 
microvascular cross sections were examined in each sample. 
Vascular density was calculated for a standard surface area with 
the help of the sample grid as follows: the number of encountered 
microvascular proﬁ  les was divided by the examined surface area, 
which was determined by counting the number of grid squares 
of a standard size provided by the distributor. Vascular density 
was then expressed as the number of microvascular proﬁ  les on 
1 mm2 surface. In addition to microvessel density, the occurrence 
of the following features were quantiﬁ  ed: luminal endothelial 
protrusions, large empty endothelial vacuoles and basement 
membrane thickenings. The basement membrane was considered 
thickened when local exfoliations were observed in case of capil-
laries, or hyalinosis in case of arterioles. The number of micro-
vessels   displaying any of the noted abnormalities was counted 
and expressed as percentage of the total number of microvessels 
examined. Capillaries and arterioles were analyzed separately. 
Since arterioles were encountered at high enough number for 
statistical analysis only in the hippocampal vascular layer, quan-
titative analysis of arteriolar condition was performed for this 
region of the hippocampus only.
STATISTICAL ANALYSIS
Y-maze performance was statistically analyzed with a one way 
ANOVA paradigm for repeated measures. Open-ﬁ  eld behavior, 
histochemical data and electron microscopical data from CON and 
RES animals showed equal variances as determined by Levene’s 
test for equality of variance (p > 0.05) and there was no indica-
tion that the data was not normally distributed, as was determined 
by a one-sample Kolmogorov-Smirnov test (p > 0.05). Therefore, 
differences were statistically tested using an independent samples 
Student’s T-test (2-tailed). To evaluate relationships between cer-
ebrovascular parameters and Y-maze performance, a Pearson cor-
relation analysis was applied. Data are expressed as averages ± SEM, 
p < 0.05 was considered as signiﬁ  cant.
RESULTS
SURVIVAL AND FOOD INTAKE
Animals received resveratrol in their food from 1 year of age onwards. 
Adding resveratrol to the food did not affect food intake, and body 
weight (data not shown). Before behavioral testing started, at the 
age of 18–20 months, four animals had died (2 CON and 2 RES). 
After behavioral testing, but before the end of the experiment at 
24 months, nine more animals died (4 CON and 5 RES). There 
were no signiﬁ  cant differences in mortality rate between CON and 
RES mice, and regular visual inspection did not indicate obvious 
differences in general health either.
BEHAVIORAL PERFORMANCE
In the open-ﬁ  eld test, CON and RES mice displayed the same 
amount of locomotion (total distance covered), however, the RES 
group spent about 50% more time in the center of the arena than 
the control animals (T-test, p = 0.003; Figures 1A,B).
Also during the habituation trial of the Y-maze, CON (n = 28) 
and RES (n = 28) mice displayed similar levels of activity in terms 
of arm visits and spontaneous alternations (data not shown). 
However, during the training phase, chronic resveratrol supplemen-
tation improved learning (repeated measures ANOVA for number 
of correct choices on day 1–3: F1,54 = 6.156, p = 0.016; Figure 2). 
A T-test per day showed that RES animals performed better than 
CON animals on the second day of the training phase (p < 0.05). 
The ﬁ  nal level of performance on day 3 and the retention trial on 
day 10 were not different between CON and RES.Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 4
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CHOLINERGIC CELL NUMBERS AND FIBER DENSITY
Analysis of cholinergic cell number in the nucleus basalis did not 
reveal any difference between CON (n = 11) and RES (n = 11), 
(Figure 3A). Also, cholinergic ﬁ  ber density in the CA1 and dentate 
gyrus of the hippocampus and the PARII region of the cortex was 
unchanged after RES treatment (Figures 3B–D).
CEREBROVASCULAR SYSTEM
Electron microscopical analysis of brain tissue revealed that vascular 
density in the hippocampus of RES mice was about 15% higher 
than that in the control animals (p = 0.019; Figure 4). In the parietal 
cortex, vascular density was not different between the two groups.
FIGURE 1 | Effects of chronic resveratrol supplementation on locomotor 
behavior in an open ﬁ  eld. The test duration was 5 min and locomotion of 
CON (n = 28) and RES (n = 28) animals was monitored with an automated 
video analysis system. (A) Total distance covered during the test. (B) Time 
spent in the center area (diameter: 60 cm) of the arena (*p=0.003).
FIGURE 2 | Effects of chronic resveratrol supplementation on Y-maze 
learning. The Y-maze test consisted of 3 training days and a retention day 
1 week later. Each day consisted of eight trials and the performance of the 
animals is expressed as the percentage of correct choices per day. RES 
animals (n = 28) show faster acquisition of the task then CON animals 
(n = 28), as shown on day 2 (*p = 0.016).
FIGURE 3 | Effects of chronic resveratrol supplementation on the 
cholinergic system. (A) Average cholinergic cell number per section in the 
nucleus basalis is unchanged in the resveratrol-treated animals (n = 11) versus 
control-treated animals (n = 11). (B) Cholinergic ﬁ  ber density in hippocampal 
CA1 and (C) dentate gyrus show no effect of resveratrol treatment. (D) 
Cholinergic ﬁ  ber density in the parietal cortex (PARII) does not show an effect 
of resveratrol treatment.
FIGURE 4 | Effects of chronic resveratrol supplementation on vascular 
density in the brain. In the hippocampus, resveratrol treatment caused a 
higher vascular density. This was not observed in the cortex (CON and RES 
n = 9 each) (*p = 0.019).Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 5
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The endothelial cells of cerebral microvessels exhibited two 
  discernible abnormalities. The apical surface of the   endothelial 
cells displayed microvillus-like processes into the lumen 
(Figure 5A) and empty, large vacuoles formed primarily in the 
vicinity of tight junctions (Figure 5C). The basement  membrane 
of   capillaries occasionally appeared thickened in the form of 
local exfoliations, while the arteriolar basement   membrane, 
  particularly between the endothelial and smooth muscle cells 
was affected by hyalinosis (Figure 5E). The occurrence of base-
ment membrane thickening and endothelial   processes was not 
FIGURE 5 | Effects of resveratrol supplementation on the occurrence of 
microvascular abnormalities. (A) Representative photomicrograph and (B) 
quantitative analysis of endothelial processes. Arrowheads point at the typical 
endothelial processes of a cortical capillary. (C) Representative photomicrograph 
and (D) quantitative analysis of endothelial vacuoles (*p < 0.05). 
The photomicrograph demonstrates a capillary in the hippocampus CA1 
region. Arrowheads are pointing at the large, empty endothelial vacuole. 
(E) Representative photomicrograph and (F) quantitative analysis of vascular 
basement membrane thickening. The photomicrograph demonstrates an 
arteriole in the hippocampal vascular layer. Arrowheads are pointing at healthy 
and thickened segments of the basement membrane. Abbreviations: asterisk: 
microvascular lumen, art: arterioles, cap: capillaries, e: endothelial cell, en: 
endothelial cell nucleus, p: pericyte, smc: smooth muscle cell, smn: smooth 
muscle cell nucleus (CON and RES n = 9).Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 6
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signiﬁ   cantly affected by dietary resveratrol (Figures 5B,F). 
However, the number of microvessels with endothelial vacu-
oles was signiﬁ  cantly reduced by chronic resveratrol treatment 
(Figure 5D) in both hippocampal arterioles (p < 0.05) and corti-
cal capillaries (p < 0.05).
To assess whether cognitive functioning in the aged mice was 
related to their cerebrovascular status, individual Y-maze perform-
ance was correlated with vascular parameters. The Y-maze scores 
on day 2 and 3 as well as the slope of the learning curve from 
day 1 to 3 were used as measures of cognitive functioning. Y-maze 
performance on day 2 correlated positively with capillary density 
in the cortex, although this only reached statistical signiﬁ  cance in 
the RES group (CON: R = 0.59, p = 0.09; RES: R = 0.86, p = 0.03). 
On the other hand, in the CON animals, Y-maze performance 
on day 3 showed a negative correlation with the % of endothelial 
vacuoles in the cortex (CON: R = −0.75, p = 0.02; RES: R = 0.36, 
p > 0.1), a negative correlation with endothelial processes (CON: 
R = −0.77, p = 0.04; RES: R = −0.19, p > 0.1) and a negative cor-
relation with basement membrane thickness (CON: R = −0.88, 
p = 0.01; RES: R = −0.15, p > 0.1) in the hippocampus. Also the 
slope of the Y-maze learning curve showed a negative correlation 
with a number of cortical vascular abnormalities like basement 
membrane thickness in the RES group (RES: −0.85, p = 0.03) and 
endothelial vacuoles in the CON group (CON: R = −0.69, p = 0.04). 
Most of these correlations suggest that better learning performance 
is associated with higher capillary density and lower incidence of 
vascular abnormalities.
DISCUSSION
Chronic dietary supplementation with the natural polyphenol 
  resveratrol improved performance of aged mice in the acquisi-
tion of a Y-maze task and increased the exploration of the center 
area of an open-ﬁ  eld test. The improvement in cognitive perform-
ance as observed in the Y-maze was paralleled by an increased 
 microvascular density in the hippocampus and decreased number 
of vacuolar abnormalities in both hippocampal and cortical micro-
vascular endothelial cells.
Spatial orientation and memory performance in the Y-maze is 
at least partly dependent on the hippocampus, a brain area often 
affected by aging (Erickson and Barnes, 2003; Havekes et al., 2007). 
We found that resveratrol-treated animals performed   better dur-
ing the acquisition of this task. Although differences in general 
activity and anxiety are potentially confounding factors in most 
learning tasks, it is unlikely that this explains the results of the 
Y-maze test in the present study. First, during the free exploration 
in the habituation trial before the start of training, resveratrol-
supplemented and control mice showed similar levels of explora-
tive activity in terms of arm visits and spontaneous alternations. 
Second, during the training, all animals entered the maze in every 
trial and latencies were not different for treated versus untreated 
animals. Furthermore, although the data from the open-ﬁ  eld test 
show an increased exploration in the center of the arena as opposed 
to the outer rim, it conﬁ  rms that there was no effect of resveratrol 
treatment on general   locomotor   activity, since the total distance 
covered by animals was the same for both groups. Taken together, 
the increased performance of the resveratrol-treated animals during 
the acquisition phase of the Y-maze task most likely indicates an 
improved cognitive   performance or, alternatively, a reduction in 
the well-established aging-related decline in cognitive performance 
(Erickson and Barnes, 2003).
The mechanisms behind resveratrol-induced preservation of 
cognitive performance during aging are most likely multifacto-
rial. In the present study improved performance in the  resveratrol-
  supplemented group was paralleled by higher hippocampal 
microvessel density and less aberrant microvessels in both hip-
pocampus and cortex compared to the control group. We also tested 
for associations between Y-maze performance and cerebrovascular 
parameters on an individual level by means of a correlative analysis. 
Clearly, this correlative analysis should be interpreted with cau-
tion given the high number of possible associations tested and 
the risk of type-1 statistical errors. On the other hand, despite the 
restricted number of animals included in the EM study and the 
reasonably low variation in the various measures, it is striking that 
all signiﬁ  cant correlations point in the same direction, that is, better 
performance in the Y-maze was associated with higher capillary 
density and a lower incidence of vascular abnormalities in either 
cortex or hippocampus. These ﬁ  ndings thus support the idea that 
beneﬁ  cial effects of resveratrol on cognitive function are mediated 
via the cerebrovascular system. A higher microvascular density and 
increased cerebral blood ﬂ  ow might improve performance directly 
by increasing glucose and oxygen supply to relevant brain areas 
(Gold, 2005; Zlokovic, 2008). Additionally, microvessels potentially 
provide a source of trophic factors such as insulin-like growth factor 
(IGF)-1 and nerve growth factor that support neuronal function. 
These factors have been shown to decrease in aging together with 
reductions in cortical microvascular density (Sonntag et al., 1997) 
and microvascular growth (Ingraham et al., 2008), and are also 
implicated in age-related cognitive decline (Ramsey et al., 2004).
An increased microvascular density can be explained in two 
ways. First, resveratrol could actively stimulate angiogenesis or 
second, resveratrol could prevent an age-related decline in angio-
genesis and/or deterioration of vascular status. Since resveratrol has 
been reported to inhibit angiogenesis in vitro (Igura et al., 2001; Cao 
et al., 2004), it seems more likely that resveratrol supplementation 
in the present study attenuated the age-related decline in vascular 
density and maintained normal levels of angiogenesis as opposed 
to an increase in angiogenesis and vessel density over control levels. 
Moreover, resveratrol appeared to prevent or delay the occurrence 
of microvascular abnormalities, another hallmark of aging-related 
decline in the microvascular condition.
There are multiple pathways via which resveratrol could prevent 
age-related decline in vascular density and occurrence of microv-
ascular abnormalities. First, resveratrols’ antioxidative properties 
prevent oxidation of membrane lipids and ensure normal cellular 
functioning, whereas excessive oxidative stress has been reported 
to impair angiogenesis (Urbich et al., 2002; Michaud et al., 2006). 
Second, resveratrol is likely to inﬂ  uence cerebrovascular health by 
its capability to reduce platelet aggregation (Bertelli et al., 1995; 
Stef et al., 2006) and its facilitation of endothelium-dependent 
vascular relaxation (Rush et al., 2007). Finally, resveratrol may 
be able to prevent the aging-related decline in cerebrovascular 
condition via the activation of biochemical pathways that involve 
SIRT1 (a sirtuin gene encoding a NAD+ dependent deacetylase). 
Resveratrol has been categorized as a sirtuin-activating compound Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 7
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which is known to mimic caloric restriction and was found to 
increase life span in lower organisms via the activation of sir2, a 
conserved deacetylase proposed to underlie the beneﬁ  cial effects 
of caloric restriction (Howitz et al., 2003; Wood et al., 2004). In 
mammalian cells, resveratrol and/or resveratrol-activated SIRT1 
have been found to induce processes that promote cellular func-
tioning and control cell death (Picard et al., 2004; Chen et al., 2005; 
Kolthur-Seetharam et al., 2006; Alvira et al., 2007; Okawara et al., 
2007; Barger et al., 2008; Pearson et al., 2008; Raval et al., 2008). The 
ﬁ  nding that caloric restriction itself beneﬁ  ts cortical microvascular 
density and local cerebral blood ﬂ  ow in aged rats (Lynch et al., 
1999) supports the idea of this pathway as a potential mechanism 
of action. Additionally, both resveratrol and SIRT1 were shown to 
exert vasoprotective effects against oxidative stress and inﬂ  amma-
tory factors (Csiszar et al., 2008).
More recent studies found compelling effects of resveratrol, 
as a substance that potentially enhances the health and lifespan 
of organisms. For instance, Barger et al. found that even a low 
dose of resveratrol partially mimics caloric restriction in mice 
by assessing transcription patterns in several tissues, including 
the brain. Resveratrol supplementation was around 25% of the 
dosage used in the current study. Interestingly, chronic resveratrol 
supplementation in mice on a high-calorie diet showed prolonged 
survival and a prolonged general health (Baur et al., 2006). In this 
particular study, mice received resveratrol in a chronic fashion, 
doses and timing highly comparable to our experimental design. 
The authors found that resveratrol produces changes associated 
with a longer lifespan, resulting in a physiological shift of middle-
aged mice on a high-calorie diet towards that of mice on a standard 
diet. In a more recent study by the same group, resveratrol had no 
effects on survival in normal mice, but they did ﬁ  nd that resvera-
trol mimics transcriptional patterns in different tissues (Pearson 
et al., 2008). Although we did not assess survival, but focused on 
neurobiological function and cerebrovascular condition, our data 
suggest that one of the target-systems for resveratrol to exert its 
beneﬁ  cial effects can be found in a preservation of the cerebrov-
ascular system.
Interestingly, the effects of resveratrol appear to be the most 
prominent in the hippocampus as reﬂ  ected by the region-speciﬁ  c 
increase in microvascular density. As an interesting parallel, the 
beneﬁ  cial effects of physical exercise on the microvasculature, 
have also shown a high degree of regional speciﬁ  city, even within 
the hippocampal formation (Pereira et al., 2007; Van der Borght 
et al., 2009). This demonstrates that, even though the hippocampus 
is one of the most vulnerable regions when it comes to age-related 
pathology, the hippocampal microvasculature contains adaptive 
potential and may prove to be an interesting therapeutic target.
In contrast to the results on the cerebrovascular level, we did 
not ﬁ  nd any effects of chronic resveratrol treatment on structural 
parameters of the cholinergic system i.e. cholinergic cell number 
and ﬁ  ber density. The lack of effects on neuronal level is actu-
ally paralleled by previous studies on aging, where no quantitative 
difference in the number of neurons or synapses were found (for 
review see Coleman and Flood, 1987). Furthermore, previous stud-
ies on dietary supplementation in Tg2576 transgenic mice, a model 
for Alzheimer’s disease, found a strong effect on spatial learning, but 
no effects on histological read outs (Stackman et al., 2003; Quinn 
et al., 2007). A recent study, however, argues in favor of the direct 
effects of resveratrol on neuronal health since they showed a reduc-
tion in neurodegeneration (cell death) in parallel with a rescued 
cognitive functioning after resveratrol treatment (Kim et al., 2007). 
However, this study used intracerebroventricular injections which 
leads to a direct treatment of neuronal tissue. When applied in an 
oral fashion, resveratrol is required to enter the brain in sufﬁ  cient 
levels in order to exhibit its direct effects on neuronal health. In the 
present study we show that resveratrol is present in the blood, ﬂ  uc-
tuating according to daily food intake. However, the bioavailability 
of resveratrol and relative concentrations in different tissues are still 
under discussion (Rossi et al., 2008) and it is unknown whether suf-
ﬁ  cient concentrations of resveratrol cross the blood-brain barrier 
to exert direct beneﬁ  cial effects at the neuronal level. This should 
be considered when evaluating the relevance of the physiological 
effects of resveratrol in view of treatment options.
In conclusion, this is the ﬁ  rst study to show beneﬁ  cial effects of 
long-term dietary supplementation with the natural polyphenol 
resveratrol on cognitive functioning and cerebrovascular condition. 
The status of the cerebrovascular system and the neurovascular unit 
have gained increasing interest as a potential target for treatment of 
aging associated disorders of the brain (Iadecola, 2004; Zlokovic, 
2008). In this light, we propose that ingestion of resveratrol, thereby 
targeting the integrity of the cerebrovascular system, can be an effec-
tive and simple method to support healthy aging of the brain.
ACKNOWLEDGMENTS
We thank Gerrit Witte and Martijn de Wilde at Danone Research for 
determining resveratrol levels in the blood samples. We thank Jan 
Keijser of the Department for Molecular Neurobiology in Haren 
for his assistance in the Quantimet analysis.
REFERENCES
Alvira, D., Yeste-Velasco, M., Folch, 
J., Verdaguer, E., Canudas, A. M., 
Pallas, M., and Camins, A. (2007). 
Comparative analysis of the effects of 
resveratrol in two apoptotic models: 
inhibition of complex I and potassium 
deprivation in cerebellar neurons. 
Neuroscience 147, 746–756.
Amenta, F., Ferrante, F., Mancini, M., 
Sabbatini, M., Vega, J. A., and Zaccheo, 
D. (1995). Effect of long-term treat-
ment with the dihydropyridine-type 
calcium channel blocker darodipine 
(PY 108-068) on the cerebral capillary 
network in aged rats. Mech. Ageing 
Dev. 78, 27–37.
Barger, J. L., Kayo, T., Vann, J. M., Arias, 
E. B., Wang, J., Hacker, T. A., Wang, 
Y., Raederstorff, D., Morrow, J. D., 
Leeuwenburgh, C., Allison, D. B., 
Saupe, K. W., Cartee, G. D., Weindruch, 
R., and Prolla, T. A. (2008). A low dose 
of dietary resveratrol partially mim-
ics caloric restriction and retards 
aging parameters in mice. PLoS 
ONE 3, e2264. doi:10.1371/journal.
pone.0002264.
Baur, J. A., Pearson, K. J., Price, N. L., 
Jamieson, H. A., Lerin, C., Kalra, A., 
Prabhu, V. V., Allard, J. S., Lopez-Lluch, 
G., Lewis, K., Pistell, P. J., Poosala, S., 
Becker, K. G., Boss, O., Gwinn, D., Wang, 
M., Ramaswamy, S., Fishbein, K. W., 
Spencer, R. G., Lakatta, E. G., Le Couteur, 
D., Shaw, R. J., Navas, P., Puigserver, P., 
Ingram, D. K., de Cabo, R., and Sinclair, 
D. A. (2006). Resveratrol improves health 
and survival of mice on a high-calorie 
diet. Nature 444, 337–342.
Baur, J. A., and Sinclair, D. A. (2006). 
Therapeutic potential of resveratrol: 
the in vivo evidence. Nat. Rev. Drug 
Discov. 5, 493–506.
Bertelli, A. A., Giovannini, L., Giannessi, 
D., Migliori, M., Bernini, W., Fregoni, 
M., and Bertelli, A. (1995). Antiplatelet 
  activity of synthetic and natural res-
veratrol in red wine. Int. J. Tissue React. 
17, 1–3.
Buee, L., Hof, P. R., Bouras, C., Delacourte, A., 
Perl, D. P., Morrison, J. H., and Fillit, H. 
M. (1994). Pathological alterations of the 
cerebral  microvasculature in Alzheimer’s 
disease and related dementing disorders. 
Acta Neuropathol. 87, 469–480.Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 8
Oomen et al.  Resveratrol preserves neurovasculature in aging
Burns, E. M., Kruckeberg, T. W., and 
Gaetano, P. K. (1981). Changes with 
age in cerebral capillary morphology. 
Neurobiol. Aging 2, 283–291.
Cao, Z., Fang, J., Xia, C., Shi, X., and 
Jiang, B. H. (2004). trans-3,4,5’-
Trihydroxystibene inhibits hypoxia-
inducible factor 1alpha and vascular 
endothelial growth factor expression 
in human ovarian cancer cells. Clin. 
Cancer Res. 10, 5253–5263.
Chen, J., Zhou, Y., Mueller-Steiner, S., 
Chen, L. F., Kwon, H., Yi, S., Mucke, 
L., and Gan, L. (2005). SIRT1 protects 
against microglia-dependent amyloid-
beta toxicity through inhibiting NF-
kappaB signaling. J. Biol. Chem. 280, 
40364–40374.
Coleman, P. D., and Flood, D. G. (1987). 
Neuron numbers and dendritic extent 
in normal aging and Alzheimer’s dis-
ease. Neurobiol. Aging 8, 521–545.
Csiszar, A., Labinskyy, N., Podlutsky, A., 
Kaminski, P. M., Wolin, M. S., Zhang, 
C., Mukhopadhyay, P., Pacher, P., Hu, 
F., de Cabo, R., Ballabh, P., and Ungvari, 
Z. (2008). Vasoprotective effects of 
resveratrol and SIRT1: attenuation 
of cigarette smoke-induced oxidative 
stress and proinﬂ  ammatory pheno-
typic alterations. Am. J. Physiol. Heart 
Circ. Physiol. 294, H2721–2735.
Das, S., Alagappan, V. K., Bagchi, D., 
Sharma, H. S., Maulik, N., and Das, 
D. K. (2005). Coordinated induction 
of iNOS-VEGF-KDR-eNOS after 
resveratrol consumption: a potential 
mechanism for resveratrol precondi-
tioning of the heart. Vascul. Pharmacol. 
42, 281–289.
De Jong, G. I., De Vos, R. A., Steur, 
E. N., and Luiten, P. G. (1997). 
Cerebrovascular hypoperfusion: a risk 
factor for Alzheimer’s disease? Animal 
model and postmortem human stud-
ies. Ann. N. Y. Acad. Sci. 826, 56–74.
de Wilde, M. C., Farkas, E., Gerrits, M., 
Kiliaan, A. J., and Luiten, P. G. (2002). 
The effect of n-3 polyunsaturated 
fatty acid-rich diets on cognitive and 
cerebrovascular parameters in chronic 
cerebral hypoperfusion. Brain Res. 
947, 166–173.
Dong, W., Li, N., Gao, D., Zhen, H., Zhang, 
X., and Li, F. (2008). Resveratrol 
attenuates ischemic brain damage 
in the delayed phase after stroke and 
induces messenger RNA and protein 
express for angiogenic factors. J. Vasc. 
Surg. 48, 709–714.
Erickson, C. A., and Barnes, C. A. (2003). 
The neurobiology of memory changes 
in normal aging. Exp. Gerontol. 38, 
61–69.
Farkas, E., De Vos, R. A., Jansen Steur, 
E. N., and Luiten, P. G. (2000). Are 
Alzheimer’s disease, hypertension, 
and cerebrocapillary damage related? 
Neurobiol. Aging 21, 235–243.
Farkas, E., and Luiten, P. G. (2001). 
Cerebral microvascular pathology in 
aging and Alzheimer’s disease. Prog. 
Neurobiol. 64, 575–611.
Farkas, E., Luiten, P. G., and Bari, F. 
(2007). Permanent, bilateral com-
mon carotid artery occlusion in the 
rat: a model for chronic cerebral 
hypoperfusion-related neurodegen-
erative diseases. Brain Res. Rev. 54, 
162–180.
Farkas, I. G., Czigner, A., Farkas, E., Dobo, 
E., Soos, K., Penke, B., Endresz, V., 
and Mihaly, A. (2003). Beta-amyloid 
peptide-induced blood-brain barrier 
disruption facilitates T-cell entry into 
the rat brain. Acta Histochem. 105, 
115–125.
Fitzpatrick, D. F., Hirschﬁ  eld, S. L., and 
Coffey, R. G. (1993). Endothelium-
dependent vasorelaxing activity of 
wine and other grape products. Am. 
J. Physiol. 265, H774–778.
Frankel, E. N., Waterhouse, A. L., and 
Kinsella, J. E. (1993). Inhibition of 
human LDL oxidation by resveratrol. 
Lancet 341, 1103–1104.
Fremont, L. (2000). Biological effects of 
resveratrol. Life Sci. 66, 663–673.
Fremont, L., Belguendouz, L., and 
Delpal, S. (1999). Antioxidant activ-
ity of resveratrol and alcohol-free wine 
polyphenols related to LDL oxidation 
and polyunsaturated fatty acids. Life 
Sci. 64, 2511–2521.
Gehm, B. D., McAndrews, J. M., Chien, P. Y., 
and Jameson, J. L. (1997). Resveratrol, 
a polyphenolic compound found in 
grapes and wine, is an agonist for the 
estrogen receptor. Proc. Natl. Acad. Sci. 
U.S.A. 94, 14138–14143.
Gold, P. E. (2005). Glucose and age-related 
changes in memory. Neurobiol. Aging 
26(Suppl. 1), 60–64.
Havekes, R., Timmer, M., and Van der Zee, 
E. A. (2007). Regional differences in 
hippocampal PKA immunoreactivity 
after training and reversal training in 
a spatial Y-maze task. Hippocampus 
17, 338–348.
Hedreen, J. C., Bacon, S. J., and Price, D. 
L. (1985). A modiﬁ  ed histochemical 
technique to visualize acetylcholineste-
rase-containing axons. J. Histochem. 
Cytochem. 33, 134–140.
Howitz, K. T., Bitterman, K. J., Cohen, 
H. Y., Lamming, D. W., Lavu, S., 
Wood, J. G., Zipkin, R. E., Chung, P., 
Kisielewski, A., Zhang, L. L., Scherer, 
B., and Sinclair, D. A. (2003). Small 
molecule activators of sirtuins extend 
Saccharomyces cerevisiae lifespan. 
Nature 425, 191–196.
Iadecola, C. (2004). Neurovascular regu-
lation in the normal brain and in 
Alzheimer’s disease. Nat. Rev. Neurosci. 
5, 347–360.
Igura, K., Ohta, T., Kuroda, Y., and Kaji, 
K. (2001). Resveratrol and quercetin 
inhibit angiogenesis in vitro. Cancer 
Lett. 171, 11–16.
Ingraham, J. P., Forbes, M. E., Riddle, D. 
R., and Sonntag, W. E. (2008). Aging 
reduces hypoxia-induced microvascu-
lar growth in the rodent hippocampus. 
J. Gerontol. A Biol. Sci. Med. Sci. 63, 
12–20.
Jager, U., and Nguyen-Duong, H. (1999). 
Relaxant effect of trans-resveratrol 
on isolated porcine coronary arteries. 
Arzneimittelforschung 49, 207–211.
Jang, J. H. and Surh, Y. J. (2003). 
Protective effect of resveratrol on 
beta-amyloid-induced oxidative 
PC12 cell death. Free Radic. Biol. Med. 
34, 1100–1110.
Jang, M., Cai, L., Udeani, G. O., Slowing, K. 
V., Thomas, C. F., Beecher, C. W., Fong, 
H. H., Farnsworth, N. R., Kinghorn, 
A. D., Mehta, R. G., Moon, R. C., and 
Pezzuto, J. M. (1997). Cancer chemo-
preventive activity of resveratrol, a 
natural product derived from grapes. 
Science 275, 218–220.
Keuker, J. I., Luiten, P. G., and Fuchs, E. 
(2000). Capillary changes in hippoc-
ampal CA1 and CA3 areas of the aging 
rhesus monkey. Acta Neuropathol. 100, 
665–672.
Kim, D., Nguyen, M. D., Dobbin, M. M., 
Fischer, A., Sananbenesi, F., Rodgers, 
J. T., Delalle, I., Baur, J. A., Sui, G., 
Armour, S. M., Puigserver, P., Sinclair, 
D. A., and Tsai, L. H. (2007). SIRT1 
deacetylase protects against neurode-
generation in models for Alzheimer’s 
disease and amyotrophic lateral scle-
rosis. EMBO J. 26, 3169–3179.
Kolthur-Seetharam, U., Dantzer, F., 
McBurney, M. W., de Murcia, G., and 
Sassone-Corsi, P. (2006). Control of 
AIF-mediated cell death by the func-
tional interplay of SIRT1 and PARP-1 
in response to DNA damage. Cell Cycle 
5, 873–877.
Kopp, P. (1998). Resveratrol, a phytoes-
trogen found in red wine. A possible 
explanation for the conundrum of the 
‘French paradox’? Eur. J. Endocrinol. 
138, 619–620.
Labinskyy, N., Csiszar, A., Veress, G., Stef, 
G., Pacher, P., Oroszi, G., Wu, J., and 
Ungvari, Z. (2006). Vascular dys-
function in aging: potential effects 
of resveratrol, an anti-inﬂ  ammatory 
phytoestrogen. Curr. Med. Chem. 13, 
989–996.
Lee, E. Y., Lee, S. Y., Lee, T. S., Chi, J. 
G., Choi, W., and Suh, Y. H. (2000). 
Ultrastructural changes in microves-
sel with age in the hippocampus of 
 senescence-accelerated mouse (SAM)-
P/10. Exp. Aging Res. 26, 3–14.
Lu, K. T., Chiou, R. Y., Chen, L. G., Chen, M. 
H., Tseng, W. T., Hsieh, H. T., and Yang, 
Y. L. (2006). Neuroprotective effects 
of resveratrol on cerebral ischemia-
induced neuron loss  mediated by free 
radical scavenging and cerebral blood 
ﬂ  ow elevation. J. Agric. Food Chem. 54, 
3126–3131.
Lynch, C. D., Cooney, P. T., Bennett, S. A., 
Thornton, P. L., Khan, A. S., Ingram, R. 
L., and Sonntag, W. E. (1999). Effects 
of moderate caloric restriction on 
cortical microvascular density and 
local cerebral blood ﬂ  ow in aged rats. 
Neurobiol. Aging 20, 191–200.
Michaud, S. E., Dussault, S., Groleau, J., 
Haddad, P., and Rivard, A. (2006). 
Cigarette smoke exposure impairs 
VEGF-induced endothelial cell 
migration: role of NO and reactive 
oxygen species. J. Mol. Cell. Cardiol. 
41, 275–284.
Mizutani, K., Ikeda, K., Kawai, Y., and 
Yamori, Y. (2001). Protective effect 
of resveratrol on oxidative damage 
in male and female stroke-prone 
spontaneously hypertensive rats. 
Clin. Exp. Pharmacol. Physiol. 28, 
55–59.
Okawara, M., Katsuki, H., Kurimoto, E., 
Shibata, H., Kume, T., and Akaike, A. 
(2007). Resveratrol protects dopamin-
ergic neurons in midbrain slice cul-
ture from multiple insults. Biochem. 
Pharmacol. 73, 550–560.
Pearson, K. J., Baur, J. A., Lewis, K. N., 
Peshkin, L., Price, N. L., Labinskyy, N., 
Swindell, W. R., Kamara, D., Minor, R. 
K., Perez, E., Jamieson, H. A., Zhang, 
Y., Dunn, S. R., Sharma, K., Pleshko, 
N., Woollett, L. A., Csiszar, A., Ikeno, 
Y., Le Couteur, D., Elliott, P. J., Becker, 
K. G., Navas, P., Ingram, D. K., Wolf, 
N. S., Ungvari, Z., Sinclair, D. A., and 
de Cabo, R. (2008). Resveratrol delays 
age-related deterioration and mim-
ics transcriptional aspects of dietary 
restriction without extending life span. 
Cell Metab. 8, 157–168.
Pereira, A. C., Huddleston, D. E., 
Brickman, A. M., Sosunov, A. A., 
Hen, R., McKhann, G. M., Sloan, R., 
Gage, F. H., Brown, T. R., and Small, 
S. A. (2007). An in vivo correlate of 
exercise-induced neurogenesis in the 
adult dentate gyrus. Proc. Natl. Acad. 
Sci. U.S.A. 104, 5638–5643.
Picard, F., Kurtev, M., Chung, N., Topark-
Ngarm, A., Senawong, T., Machado De 
Oliveira, R., Leid, M., McBurney, M. 
W., and Guarente, L. (2004). Sirt1 pro-
motes fat mobilization in white adi-
pocytes by repressing PPAR-gamma. 
Nature 429, 771–776.
Quinn, J. F., Bussiere, J. R., Hammond, R. 
S., Montine, T. J., Henson, E., Jones, 
R. E. and Stackman, R. W. Jr. (2007). 
Chronic dietary alpha-lipoic acid 
reduces deﬁ  cits in hippocampal mem-
ory of aged Tg2576 mice. Neurobiol. 
Aging 28, 213–225.
Ramsey, M. M., Weiner, J. L., Moore, T. 
P., Carter, C. S., and Sonntag, W. E. 
(2004). Growth hormone treatment Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  4 | 9
Oomen et al.  Resveratrol preserves neurovasculature in aging
Sonntag, W. E., Lynch, C. D., Cooney, P. T., 
and Hutchins, P. M. (1997). Decreases 
in cerebral microvasculature with 
age are associated with the decline 
in growth hormone and insulin-like 
growth factor 1. Endocrinology 138, 
3515–3520.
Stackman, R. W., Eckenstein, F., Frei, B., 
Kulhanek, D., Nowlin, J., and Quinn, 
J. F. (2003). Prevention of age-related 
spatial memory deﬁ  cits in a transgenic 
mouse model of Alzheimer’s disease 
by chronic Ginkgo biloba treatment. 
Exp. Neurol. 184, 510–520.
Stef, G., Csiszar, A., Lerea, K., Ungvari, 
Z., and Veress, G. (2006). Resveratrol 
inhibits aggregation of platelets from 
high-risk cardiac patients with aspirin 
resistance. J. Cardiovasc. Pharmacol. 
48, 1–5.
Urbich, C., Dernbach, E., Aicher, A., 
Zeiher, A. M., and Dimmeler, S. (2002). 
CD40 ligand inhibits endothelial cell 
migration by increasing production 
of endothelial reactive oxygen species. 
Circulation 106, 981–986.
Van der Borght, K., Kobor-Nyakas, D. E., 
Klauke, K., Eggen, B. J., Nyakas, C., Van 
der Zee, E. A., and Meerlo, P. (2009). 
Physical exercise leads to rapid adap-
tations in hippocampal vasculature: 
temporal dynamics and relationship 
to cell proliferation and neurogenesis. 
Hippocampus 19, 928–936.
attenuates age-related changes in 
  hippocampal short-term plasticity 
and spatial learning. Neuroscience 
129, 119–127.
Raval, A. P., Lin, H. W., Dave, K. R., Defazio, 
R. A., Morte, D. D., Kim, E. J., and Perez-
Pinzon, M. A. (2008). Resveratrol and 
ischemic preconditioning in the brain. 
Curr. Med. Chem. 15, 1545–1551.
Renaud, S., and de Lorgeril, M. (1992). 
Wine, alcohol, platelets, and the 
French paradox for coronary heart 
disease. Lancet 339, 1523–1526.
Riddle, D. R., Sonntag, W. E., and 
Lichtenwalner, R. J. (2003). 
Microvascular plasticity in aging. 
Ageing Res. Rev. 2, 149–168.
Rossi, L., Mazzitelli, S., Arciello, M., 
Capo, C. R., and Rotilio, G. (2008). 
Beneﬁ  ts from dietary polyphenols for 
brain aging and Alzheimer’s disease. 
Neurochem. Res. 33, 2390–2400.
Rush, J. W., Quadrilatero, J., Levy, A. S. and 
Ford, R. J. (2007). Chronic resveratrol 
enhances endothelium-dependent 
relaxation but does not alter eNOS lev-
els in aorta of spontaneously hyperten-
sive rats. Exp. Biol. Med. 232, 814–822.
Sonntag, W. E., Lynch, C., Thornton, P., 
Khan, A., Bennett, S., and Ingram, 
R. (2000). The effects of growth 
hormone and IGF-1 deficiency on 
  cerebrovascular and brain ageing. J. 
Anat. 197(Pt 4) 575–585.
Virgili, M., and Contestabile, A. (2000). 
Partial neuroprotection of in vivo 
excitotoxic brain damage by chronic 
administration of the red wine anti-
oxidant agent, trans-resveratrol in rats. 
Neurosci. Lett. 281, 123–126.
Wang, Q., Xu, J., Rottinghaus, G. E., 
Simonyi, A., Lubahn, D., Sun, G. Y., 
and Sun, A. Y. (2002). Resveratrol 
protects against global cerebral 
ischemic injury in gerbils. Brain Res. 
958, 439–447.
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., 
Helfand, S. L., Tatar, M., and Sinclair, D. 
(2004). Sirtuin activators mimic caloric 
restriction and delay ageing in metazo-
ans. Nature 430, 686–689.
Wu, J. M., Wang, Z. R., Hsieh, T. C., Bruder, 
J. L., Zou, J. G. and Huang, Y. Z. (2001). 
Mechanism of cardioprotection by 
resveratrol, a phenolic antioxidant 
present in red wine (Review). Int. J. 
Mol. Med. 8, 3–17.
Zhang, H., Schools, G. P., Lei, T., Wang, W., 
Kimelberg, H. K., and Zhou, M. (2008). 
Resveratrol attenuates early pyramidal 
neuron excitability impairment and 
death in acute rat hippocampal slices 
caused by oxygen-glucose deprivation. 
Exp. Neurol. 212, 44–52.
Zlokovic, B. V. (2008). The blood-
brain barrier in health and chronic 
 neurodegenerative  disorders.  Neuron 
57, 178–201.
Conflict of Interest Statement: The 
research conducted in the paper was 
financially supported by Danone 
Research, Centre for Specialised nutrition. 
Danone Research has a ﬁ  nancial interest 
in the component resveratrol. Eline van 
der Beek is employed at Danone Research, 
Centre for Specialised Nutrition in 
Wageningen, the Netherlands. Charlotte 
Oomen, Eszter Farkas, Viktor Roman, 
Paul Luiten and Peter Meerlo, have no 
actual or potential conﬂ  ict of interests 
concerning the research presented in 
the paper.
Received: 31 July 2009; paper pending 
published: 10 October 2009; accepted: 
23 November 2009; published online: 09 
December 2009.
Citation: Oomen CA, Farkas E, Roman V, 
van der Beek EM, Luiten PGM and Meerlo 
P (2009) Resveratrol preserves cerebrovas-
cular density and cognitive function in 
aging mice. Front. Ag. Neurosci. 1:4. doi: 
10.3389/neuro.24.004.2009
Copyright © 2009 Oomen, Farkas, Roman, 
van der Beek, Luiten and Meerlo. This is 
an open-access article subject to an exclu-
sive license agreement between the authors 
and the Frontiers Research Foundation, 
which permits unrestricted use, distribu-
tion, and reproduction in any medium, 
provided the original authors and source 
are credited.